Literature DB >> 3364762

Effects of etomidate, midazolam, and thiopental on median nerve somatosensory evoked potentials and the additive effects of fentanyl and nitrous oxide.

A Koht1, W Schütz, G Schmidt, J Schramm, E Watanabe.   

Abstract

In 30 patients undergoing spinal disc operations, the effects of bolus injections followed by intravenous infusions of thiopental, etomidate, and midazolam on median nerve somatosensory-evoked potentials (SSEPs) were studied. Possible additive effects of fentanyl and nitrous oxide were also evaluated. Serial SSEP measurements were made before and for 25 minutes after the start of anesthesia. After induction with one of the three intravenous agents, fentanyl (10 micrograms/kg) was administered and SSEPs were again measured 1 and 5 minutes after administration. Sixty-five% nitrous oxide in 35% oxygen was administered after tracheal intubation and was followed by final SSEP measurements. The three intravenous agents affected SSEP signals differently. Etomidate increased both amplitude and latency. Thiopental decreased amplitude and increased latency. Midazolam had no effect on amplitude but increased latency. The addition of fentanyl and nitrous oxide had different effects in response to the three intravenous induction agents. This study emphasizes the differences in SSEP responses not only to different intravenous induction agents but also to the addition of fentanyl and nitrous oxide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3364762

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  17 in total

1.  Cortico-centric effects of general anesthetics on cerebrocortical evoked potentials.

Authors:  Logan J Voss; James W Sleigh
Journal:  Neurosci Bull       Date:  2015-12       Impact factor: 5.203

2.  Effects of different etomidate doses on intraoperative somatosensory-evoked potential monitoring.

Authors:  X-L Meng; L-W Wang; W Zhao; X-Y Guo
Journal:  Ir J Med Sci       Date:  2014-07-25       Impact factor: 1.568

3.  Neurophysiologic monitoring in posterior fossa surgery. I. Technical principles, applicability and limitations.

Authors:  J Schramm; E Watanabe; C Strauss; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  The effect of midazolam on median nerve somatosensory evoked potentials.

Authors:  K Lauer; C Munshi; S Larson
Journal:  J Clin Monit       Date:  1994-05

5.  A prospective study of outcome predictors after severe brain injury in children.

Authors:  B G Carter; W Butt
Journal:  Intensive Care Med       Date:  2005-04-28       Impact factor: 17.440

6.  Visual evoked potentials during etomidate administration in humans.

Authors:  O Z Chi; J Subramoni; D Jasaitis
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

7.  Somatosensory Evoked Potentials suppression due to remifentanil during spinal operations; a prospective clinical study.

Authors:  Irene Asouhidou; Vasilios Katsaridis; Georgios Vaidis; Polimnia Ioannou; Panagiotis Givissis; Anastasios Christodoulou; Georgios Georgiadis
Journal:  Scoliosis       Date:  2010-05-12

8.  Systemic lidocaine and human somatosensory-evoked potentials during sufentanil-isoflurane anaesthesia.

Authors:  A Schubert; M G Licina; G M Glaze; L Paranandi
Journal:  Can J Anaesth       Date:  1992-07       Impact factor: 5.063

9.  Hypothermia after CPR prolongs conduction times of somatosensory evoked potentials.

Authors:  Aline Bouwes; Patty G G Doesborg; D Martin Laman; Johannes H T M Koelman; Jaap G Imanse; Selma C Tromp; Björn M van Geel; Elly L van der Kooi; Eveline G J Zandbergen; Janneke Horn
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

10.  A clinical and EEG scoring system that predicts early cortical response (N20) to somatosensory evoked potentials and outcome after cardiac arrest.

Authors:  Cédric Daubin; Damien Guillotin; Olivier Etard; Cathy Gaillard; Damien du Cheyron; Michel Ramakers; Bruno Bouchet; Jean-Jacques Parienti; Pierre Charbonneau
Journal:  BMC Cardiovasc Disord       Date:  2008-12-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.